Related Experiment Video
Updated: Jun 23, 2026
10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases
Amalia A Sofianidi1, Evangelia Panagodimou2, Emmanouil Kalampokas2
1Oncology Unit, Aretaieion University Hospital, National and Kapodistrian University of Athens School of Medicine, Vasilissis Sofias 76, Athens, 115 28, Greece. amaliasof@med.uoa.gr.
Current Oncology Reports
|June 22, 2026
Summary
Sacituzumab govitecan shows promise for gynecologic cancers. Ongoing trials in cervical, ovarian, and endometrial cancers are evaluating its efficacy and safety, with manageable toxicity observed.
Area of Science:
- Gynecologic Oncology
- Pharmacology
- Oncology
Background:
- Sacituzumab govitecan is an antibody-drug conjugate targeting TROP2.
- TROP2 is highly expressed on various cancer cells.
- It has shown efficacy in breast and lung cancers.
Purpose of the Study:
- To review the therapeutic potential of Sacituzumab govitecan in gynecologic malignancies.
- To summarize recent clinical evidence for its application in these cancers.
Main Methods:
- Review of ongoing Phase III clinical trials.
- Analysis of preliminary safety and efficacy data.
Main Results:
- Ongoing trials include cervical, ovarian, and endometrial cancers.
- Preliminary safety profile is manageable, with common toxicities like hematologic issues and alopecia.
- Mature data on survival and response rates are pending.
Conclusions:
- Sacituzumab govitecan demonstrates therapeutic potential in gynecologic cancers.
- Biomarker analyses may improve patient selection and prognosis.
- Further data from Phase III trials are crucial.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...